Show simple item record

dc.contributor.authorJones, DAen_US
dc.contributor.authorPellaton, Cen_US
dc.contributor.authorVelmurugan, Sen_US
dc.contributor.authorRathod, KSen_US
dc.contributor.authorAndiapen, Men_US
dc.contributor.authorAntoniou, Sen_US
dc.contributor.authorVan Eijl, Sen_US
dc.contributor.authorWebb, AJen_US
dc.contributor.authorWestwood, MAen_US
dc.contributor.authorParmar, MKen_US
dc.contributor.authorMathur, Aen_US
dc.contributor.authorAhluwalia, Aen_US
dc.description.abstract© 2014 American Heart Association, Inc. Rationale: Preclinical evidence demonstrates that inorganic nitrite, after its in situ conversion to nitric oxide, attenuates consequent myocardial reperfusion injury. Objective: We investigated whether intracoronary injection of nitrite during primary percutaneous coronary intervention might improve infarct size in ST-elevated myocardial infarction. Methods and Results: Patients undergoing primary percutaneous coronary intervention (n=80) were randomized to receive intracoronary (10 mL) sodium nitrite (1.8 μmol) or NaCl (placebo) before balloon inflation. The primary end point was infarct size assessed by measuring creatine kinase release. Secondary outcomes included infarct size assessed by troponin T release and by cardiac MRI on day 2. Baseline characteristics were similar between the groups. No evidence of differences in creatine kinase release (P=0.92), troponin T (P=0.85), or cardiac MRI-assessed infarct size (P=0.254) were evident. In contrast, there was a reduction in myocardial salvage index (P=0.05) and major adverse cardiac event at 1 year (2.6% versus 15.8%; P=0.04) in the nitrite group. In a 66-patient subgroup with thrombolysis in myocardial infarction ≤1 flow, there was reduced serum creatine kinase (P=0.030) and a 19% reduction in cardiac MRI-determined infarct size (P=0.034) with nitrite. No adverse effects of nitrite were detected. Conclusions: In this phase II study, intracoronary nitrite infusion did not alter infarct size, although a trend to improved myocardial salvage index and a significant reduction in major adverse cardiac event was evident. In a subgroup of patients with thrombolysis in myocardial infarction flow ≤1, nitrite reduced infarct size and major adverse cardiac event and improved myocardial salvage index, indicating that a phase III clinical trial assessing intracoronary nitrite administration as an adjunct to percutaneous coronary intervention in ST-elevated myocardial infarction patients is warranted.en_US
dc.format.extent437 - 447en_US
dc.relation.ispartofCirculation Researchen_US
dc.titleRandomized phase 2 trial of intracoronary nitrite during acute myocardial infarctionen_US
pubs.notesNot knownen_US

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record